Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Who May Qualify: 1. Subjects must be eligible for and intend to receive LEQEMBI under standard of care treatment. 2. Male and female subjects ages ≥50 years old. 3. Must be willing to comply with protocol including pupillary dilation to a minimum of 3.5 mm to allow for ocular imaging. 4. Patient or patient's legally authorized representative (LAR) (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of the study and provide signed and dated willing to sign a consent form and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations. Who Should NOT Join This Trial: 1. History of acute angle-closure glaucoma or allergic reaction to the protocol-specified ophthalmic medication for dilation of the pupils. 2. Self-reported or diagnosed history of dense cataracts or other significant media opacity that may affect clear images of the retina. 3. Subjects must not have had eye surgery in the past 2 months, be currently administering eye drops relating to previous eye surgery, 4. Unable or unwilling to comply with the protocol requirements. Always talk to your doctor about whether this trial is right for you.